Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies

Abstract

An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.

1 . A method of destroying abnormal blood vessels, the method comprising the step of administering an active biological substance comprising H1 histone to a mammal, wherein the abnormal blood vessels comprise endothelial cells having a disturbed lipid asymmetry in a membrane bilayer; and
 wherein administration of the active biological substance destroys the endothelial cells having a disturbed lipid asymmetry in a membrane bilayer, thereby destroying the abnormal blood vessels.   
     
     
         2 . The method according to  claim 1 , wherein the active biological substance is administered in conjunction with a cytostatic, a virostatic, or both a cytostatic and a virostatic. 
     
     
         3 . The method according to  claim 1 , wherein the mammal is a human. 
     
     
         4 . The method according to  claim 1 , wherein the disturbed lipid asymmetry includes an increased presence of anionic phospholipids in the membrane bilayer. 
     
     
         5 . The method according to  claim 4 , wherein the anionic phospholipids include phosphatidylserine. 
     
     
         6 . The method according to  claim 1 , wherein the active biological substance comprises about 1× 10   −1  μM to about 1×10 −2  μM of H1histone. 
     
     
         7 . The method according to  claim 1 , wherein the H1 histone is H1.0, H1.1, H1.2, H1.3, H1.4, H1.6, H1.t, H1.x, or a biologically active section thereof. 
     
     
         8 . The method according to  claim 1 , wherein the abnormal blood vessels supply a solid tumor. 
     
     
         9 . A method of diagnosing abnormal blood vessels, the method comprising the steps of:
 administering an active biological substance comprising H1 histone to a mammal suspected of having the abnormal blood vessels, wherein the abnormal blood vessels comprise endothelial cells having a disturbed lipid asymmetry in a membrane bilayer, and wherein the active biological substance destroys endothelial cells having a disturbed lipid asymmetry in a membrane bilayer; and   detecting the presence of the destroyed endothelial cells, wherein the presence of the destroyed endothelial cells is indicative of the abnormal blood vessels.   
     
     
         10 . The method according to  claim 9 , wherein the active biological substance is used in conjunction with a marker molecule for diagnostic purposes. 
     
     
         11 . The method according to  claim 9 , wherein the active biological substance is administered in conjunction with a cytostatic, a virostatic, or both a cytostatic and a virostatic. 
     
     
         12 . The method according to  claim 9 , wherein the mammal is a human. 
     
     
         13 . The method according to  claim 9 , wherein the disturbed lipid asymmetry includes an increased presence of anionic phospholipids in the outer layer of the membrane. 
     
     
         14 . The method according to  claim 13 , wherein the anionic phospholipids include phosphatidylserine. 
     
     
         15 . The method according to  claim 9 , wherein the active biological substance comprises about 1× 10   −1  μM to about 1×10 −2  μM of H1 histone. 
     
     
         16 . The method according to  claim 9 , wherein the H1 histone is H1.0, H1.1, H1.2, H1.3, H1.4, H1.6, H1.t, H1.x, or a biologically active section thereof.